Novo Holdings hot on diagnostics: This is the key to unlocking two of the largest healthcare issues

Investing in diagnostics is complicated, even for Novo Holdings – but due to the potential in the industry, the company is hungry for more acquisitions, after completing its largest-ever investment in a diagnostics company on Tuesday.

Novo Holdings Principal Investments Principal Sibel Arnes | Photo: Novo Holdings / PR

Through the acquisition of Welsh BBI group on Tuesday, Novo Holdings is demonstrating that the diagnostics area is an important field of interest for the Danish life science investor.

It has been seven years since Novo Holdings last took over majority ownership, and according to Christoffer Søderberg and Sibel Arnes from Novo Holdings' Principal Investments team, a lot is happening in this area, which makes it a highly interesting field for Novo Holdings.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs